On Apr. 9, 2020, iBio announced the signing of two agreements with the Infectious Disease Research Institute (IDRI) in support of iBio’s SARS-CoV-2 Virus-Like Particle vaccine development. IDRI, located in Seattle, will support pre-clinical development and provide clinical trial oversight, while iBio will provide process development and manufacturing services to IDRI.

Additionally, the MoU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if the Company opts to include one of IDRIﾒs novel adjuvants in the COVID-19 vaccine development program (IBIO-200).